Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claims accurately reflect the Klonopin boxed warning and related label sections on opioid co-use risks, and match the label’s directions to reserve concomitant prescribing, use lowest effective dosing/minimum duration, and monitor for sedation/respiratory depression.
Category Scores
Accurate Statements
Concomitant use with opioids increases risk of sedation/respiratory depression and can lead to coma/death.
BOXED WARNING and Warnings (Section 5) both state concomitant use of benzodiazepines (including Klonopin) and opioids may result in profound sedation, respiratory depression, coma, and death.
Reserve concomitant use.
BOXED WARNING and Section 5 state to reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Use lowest effective dose and minimum duration.
BOXED WARNING and Section 5 state to limit dosages and durations to the minimum required / prescribe the lowest effective dosages and minimum durations of concomitant use.
Close monitoring for respiratory depression and sedation.
BOXED WARNING and Section 5/Section 7 instruct to follow patients for signs and symptoms of respiratory depression and sedation / follow patients closely.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No label-contradicting or unsupported safety claims were made; the statements evaluated match the label’s core risk description and mitigation/monitoring guidance for opioid co-use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement